Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decipher LabsBOM:524752 59 Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus rates BOM:524752 with a GF Score™ of 59/100 and a GF Value™ of ₹6.28 (Fairly Valued). The stock has 3 warning signs investors should review. Among 678 Drug Manufacturers companies, Decipher Labs ranks worse than 147492.48% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Decipher Labs's Debt-to-EBITDA or its related term are showing as below:
BOM:524752'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.29 Med: 0.46 Max: 4.11
Current: -0.23
During the past 13 years, the highest Debt-to-EBITDA Ratio of Decipher Labs was 4.11. The lowest was -0.29. And the median was 0.46.
BOM:524752's Debt-to-EBITDA is ranked worse than 100% of 678
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs BOM:524752: -0.23
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Decipher Labs Debt-to-EBITDA Related Terms
Decipher Labs Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Decipher Labs's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Decipher Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decipher Labs Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Decipher Labs's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Decipher Labs's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Decipher Labs (BOM:524752) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Decipher Labs. According to the industry distribution chart, Decipher Labs ranks #999999 out of 678 companies in the Drug Manufacturers industry.
Is Decipher Labs' Debt-to-EBITDA too high?
Decipher Labs' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Decipher Labs ranks #999999 out of 678 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Decipher Labs has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Decipher Labs' Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Decipher Labs ranks #999999 out of 678 companies for Debt-to-EBITDA. This places Decipher Labs in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Decipher Labs. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decipher Labs's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decipher Labs stock overvalued right now?
Based on GuruFocus' analysis, Decipher Labs (BOM:524752) is currently considered Fairly Valued. The stock's GF Value™ is ₹6.28, compared to a current price of ₹5.98 — trading 4.8% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Decipher Labs' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Decipher Labs (BOM:524752), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Decipher Labs (BOM:524752) Overvalued in 2026?
Based on GuruFocus' analysis, Decipher Labs stock appears to be undervalued.
The current stock price of ₹5.98 is trading 4.8% below its estimated GF Value™ of ₹6.28.
GuruFocus considers Decipher Labs to be Fairly Valued.
Key valuation signals for BOM:524752:
Debt-to-EBITDA: 0.00
GF Value™: ₹6.28 vs. price of ₹5.98 (4.8% below fair value)
No single metric tells the full story. See the BOM:524752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Decipher Labs Ltd deals in the trading and manufacturing of Pharmaceutical drugs and allied products and services, and also offers services and key solutions in the Information Technology industry. It is involved in the manufacturing and marketing of its branded pharmaceutical products, and also provides drug development and manufacturing services to various formulators, manufacturers, and Research and Development agencies for their bulk needs. The group's IT Consultancy offerings include Technology Integration and Systems Consulting, Software Development Consulting, and Management of IT projects. Its reportable operating segments are: Pharmaceutical, which generates the maximum revenue, and IT Consultancy Services. Geographically, the group derives its key revenue from India.
59GF Score
Get the complete analysis for BOM:524752
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524752 has been successfully added to your 
